Oscar Health (NYSE:OSCR) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen downgraded shares of Oscar Health (NYSE:OSCR) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

Other equities research analysts have also issued reports about the stock. UBS Group lifted their target price on shares of Oscar Health from $11.00 to $12.00 and gave the company a “sell” rating in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Oscar Health in a report on Wednesday, October 8th. The Goldman Sachs Group initiated coverage on shares of Oscar Health in a research report on Tuesday, October 14th. They issued a “neutral” rating and a $17.00 target price for the company. Wells Fargo & Company lowered their price target on Oscar Health from $14.00 to $11.00 and set an “underweight” rating on the stock in a research report on Thursday, November 13th. Finally, Piper Sandler upgraded Oscar Health from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $13.00 to $25.00 in a report on Tuesday, November 25th. One investment analyst has rated the stock with a Buy rating, five have issued a Hold rating and five have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $14.86.

Oscar Health Trading Down 2.4%

Shares of OSCR stock opened at $16.77 on Friday. The company has a quick ratio of 0.92, a current ratio of 0.92 and a debt-to-equity ratio of 0.67. The firm has a market cap of $4.44 billion, a P/E ratio of -14.97 and a beta of 1.88. The company has a 50 day moving average of $18.03 and a 200-day moving average of $16.94. Oscar Health has a 12-month low of $11.20 and a 12-month high of $23.80.

Oscar Health (NYSE:OSCR) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.02. Oscar Health had a negative net margin of 2.16% and a negative return on equity of 21.50%. The company had revenue of $2.93 billion for the quarter, compared to analyst estimates of $3.09 billion. During the same quarter in the previous year, the firm posted ($0.22) earnings per share. The company’s quarterly revenue was up 23.2% compared to the same quarter last year. Sell-side analysts anticipate that Oscar Health will post 0.69 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Janet Liang sold 7,338 shares of the stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $16.59, for a total transaction of $121,737.42. Following the sale, the insider directly owned 172,527 shares of the company’s stock, valued at approximately $2,862,222.93. This represents a 4.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Mario Schlosser sold 23,965 shares of the company’s stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $16.59, for a total value of $397,579.35. Following the sale, the insider owned 477,183 shares of the company’s stock, valued at approximately $7,916,465.97. This trade represents a 4.78% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 739,472 shares of company stock valued at $12,616,880. 24.39% of the stock is owned by insiders.

Institutional Investors Weigh In On Oscar Health

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in Oscar Health by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 20,160,399 shares of the company’s stock valued at $381,636,000 after buying an additional 423,184 shares during the period. T. Rowe Price Investment Management Inc. raised its stake in shares of Oscar Health by 4.1% during the first quarter. T. Rowe Price Investment Management Inc. now owns 11,826,245 shares of the company’s stock valued at $155,043,000 after acquiring an additional 467,301 shares in the last quarter. Thrive Capital Management LLC grew its stake in Oscar Health by 33.4% in the fourth quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company’s stock worth $85,258,000 after purchasing an additional 1,588,395 shares in the last quarter. American Century Companies Inc. raised its position in Oscar Health by 89.0% during the 3rd quarter. American Century Companies Inc. now owns 5,298,340 shares of the company’s stock valued at $100,298,000 after purchasing an additional 2,495,691 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Oscar Health by 0.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,718,765 shares of the company’s stock valued at $70,400,000 after purchasing an additional 31,785 shares in the last quarter. 75.70% of the stock is currently owned by hedge funds and other institutional investors.

About Oscar Health

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.